After more than 50 years of clinical use, acquired resistance to amphotericin B, the active ingredient in AmBisome®, has rarely been reported2-5
There is growing resistance to azoles and echinocandins amongst life-threatening IFI-causing fungal species (spp.), including Candida spp. and Aspergillus spp.2,6‑8
Antifungal resistance differs between regions, countries and even hospitals; therefore, it is imperative to stay informed and keep track of resistance in your area8‑11
Azole-resistant Aspergillus infections are in danger of becoming a global health threat12
Global azole resistance prevalence in Aspergillus fumigatus* Click your country below to discover local rates of azole resistance10
With low acquired resistance, AmBisome® is ready to help you take on IFIs with confidence in the constantly evolving landscape of fungal pathogens1-5,20-24
USA: United States of America
Job code: IHQ-AMB-0534
Date of Preparation: April 2022